Pfizer Quietly Releases Statement in Response to Bombshell Project Veritas Video
After several days of silence and while much of the nation was on riot watch Friday night, pharmaceutical giant Pfizer quietly issued a statement responding to the Project Veritas video of Pfizer research director Jordon Trishton Walker talking about Pfizer exploring “directed evolution” research on the COVID-19 virus.
Pfizer denies performing gain of function or directed evolution research on the virus. However, it did say that on occasion it engineers a virus mutation, “In a limited number of cases when a full virus does not contain any known gain of function mutations, such virus may be engineered to enable the assessment of antiviral activity in cells.”
BREAKING: @Pfizer Exploring “Mutating” COVID-19 Virus For New Vaccines
“Don’t tell anyone this…There is a risk…have to be very controlled to make sure this virus you mutate doesn’t create something…the way that the virus started in Wuhan, to be honest.”#DirectedEvolutionpic.twitter.com/xaRvlD5qTo
— Project Veritas (@Project_Veritas) January 26, 2023
Pfizer Responds to Research Claims
Friday, January 27, 2023 – 08:00pm
New York, N.Y., January 27, 2023 – Allegations have recently been made related to gain of function and directed evolution research at Pfizer and the company would like to set the record straight.
In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research. Working with collaborators, we have conducted research where the original SARS-CoV-2 virus has been used to express the spike protein from new variants of concern. This work is undertaken once a new variant of concern has been identified by public health authorities. This research provides a way for us to rapidly assess the ability of an existing vaccine to induce antibodies that neutralize a newly identified variant of concern. We then make this data available through peer reviewed scientific journals and use it as one of the steps to determine whether a vaccine update is required.
In addition, to meet U.S. and global regulatory requirements for our oral treatment, PAXLOVID
, Pfizer undertakes in vitro work (e.g., in a laboratory culture dish) to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID’s two components. With a naturally evolving virus, it is important to routinely assess the activity of an antiviral. Most of this work is conducted using computer simulations or mutations of the main protease–a non-infectious part of the virus. In a limited number of cases when a full virus does not contain any known
Source: The Gateway Pundit